Search
Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
go.drugbank.com/drugs/DB16443InvestigationalIt also provided protection in non-human primates to an in vivo challenge with SARS-CoV-2[A226853]. … In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection[A226853].
Lufotrelvir
go.drugbank.com/drugs/DB16514Investigationalon preprint servers[L31733, L31125]. … Now, it is being tested regarding the novel SARS-CoV-2 virus, including studies in conjunction with [Remdesivir] to treat COVID-19 infection; in vitro data showed synergistic effects on articles published
Cyclopenthiazide
go.drugbank.com/drugs/DB13532ApprovedIn a double blind, randomized crossover study, cyclopenthiazide was effective in reducing diastolic blood pressure in mildly hypertensive non-insulin dependent diabetic patients [A27180].
Doxofylline
go.drugbank.com/drugs/DB09273InvestigationalAs a drug used in the treatment of asthma, doxofylline has shown similar efficacy to theophylline but with significantly fewer side effects in animal and human studies. … Doxofylline is a methylxanthine derivative with the presence of a dioxolane group in position 7.
beta-Hydroxybutyric acid
go.drugbank.com/drugs/DB16506InvestigationalBeta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236
Sulfameter
go.drugbank.com/drugs/DB06821ApprovedLong acting sulfonamide used in leprosy, urinary, and respiratory tract infections.
Mucor circinelloides f. lusitanicus
go.drugbank.com/drugs/DB15525ApprovedMucor circinelloides f. lusitanicus allergenic extract is used in allergenic testing.
Coffea arabica seed, roasted
go.drugbank.com/drugs/DB15603ApprovedCoffea arabica seed, roasted allergenic extract is used in allergenic testing.
Parsaclisib
go.drugbank.com/drugs/DB14867InvestigationalParsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).